Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis

A phase II, four-week, multicenter, randomized, double-blind, placebo controlled trial

Thomas J. Schnitzer, Jannie Beier, Piet Geusens, Paul Hasler, Sanjay K. Patel, Ingo Senftleber, Xavier Gitton, Alan Moore, Victor S. Sloan, G. Poór

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objective. To compare the efficacy and tolerability of the novel cyclooxygenase 2-selective inhibitor lumiracoxib with placebo and diclofenac in osteoarthritis (OA). Methods. Adults (n = 583) with knee or hip OA were randomized to receive for 4 weeks lumiracoxib 50, 100, or 200 mg twice daily or 400 mg once daily; placebo; or diclofenac 75 mg twice daily. Efficacy assessments included overall joint pain intensity and Western Ontario and McMaster Universities Osteoarthritis Index subscales; tolerability was evaluated by adverse event and physician reporting. Results. All lumiracoxib doses were superior to placebo in relieving pain, improving stiffness, and improving physical function after 4 weeks. At study endpoint, pain relief was comparable among all lumiracoxib dosages and similar to diclofenac. Lumiracoxib tolerability was superior to diclofenac and comparable to placebo. Conclusion. Lumiracoxib provides predictable and sustained relief from pain, stiffness, and impaired physical function in OA. Lumiracoxib shows clinically comparable efficacy and superior tolerability to diclofenac.

Original languageEnglish
Pages (from-to)549-557
Number of pages9
JournalArthritis Care and Research
Volume51
Issue number4
Publication statusPublished - Aug 15 2004

Fingerprint

Hip Osteoarthritis
Diclofenac
Knee
Placebos
Safety
Osteoarthritis
Pain
Knee Osteoarthritis
Cyclooxygenase 2 Inhibitors
Arthralgia
Ontario
lumiracoxib
Physicians

Keywords

  • Diclofenac
  • Lumiracoxib
  • Osteoarthritis
  • Pain relief

ASJC Scopus subject areas

  • Rheumatology

Cite this

Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis : A phase II, four-week, multicenter, randomized, double-blind, placebo controlled trial. / Schnitzer, Thomas J.; Beier, Jannie; Geusens, Piet; Hasler, Paul; Patel, Sanjay K.; Senftleber, Ingo; Gitton, Xavier; Moore, Alan; Sloan, Victor S.; Poór, G.

In: Arthritis Care and Research, Vol. 51, No. 4, 15.08.2004, p. 549-557.

Research output: Contribution to journalArticle

Schnitzer, Thomas J. ; Beier, Jannie ; Geusens, Piet ; Hasler, Paul ; Patel, Sanjay K. ; Senftleber, Ingo ; Gitton, Xavier ; Moore, Alan ; Sloan, Victor S. ; Poór, G. / Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis : A phase II, four-week, multicenter, randomized, double-blind, placebo controlled trial. In: Arthritis Care and Research. 2004 ; Vol. 51, No. 4. pp. 549-557.
@article{6631eac60c454e8bbcbe0e423e714144,
title = "Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four-week, multicenter, randomized, double-blind, placebo controlled trial",
abstract = "Objective. To compare the efficacy and tolerability of the novel cyclooxygenase 2-selective inhibitor lumiracoxib with placebo and diclofenac in osteoarthritis (OA). Methods. Adults (n = 583) with knee or hip OA were randomized to receive for 4 weeks lumiracoxib 50, 100, or 200 mg twice daily or 400 mg once daily; placebo; or diclofenac 75 mg twice daily. Efficacy assessments included overall joint pain intensity and Western Ontario and McMaster Universities Osteoarthritis Index subscales; tolerability was evaluated by adverse event and physician reporting. Results. All lumiracoxib doses were superior to placebo in relieving pain, improving stiffness, and improving physical function after 4 weeks. At study endpoint, pain relief was comparable among all lumiracoxib dosages and similar to diclofenac. Lumiracoxib tolerability was superior to diclofenac and comparable to placebo. Conclusion. Lumiracoxib provides predictable and sustained relief from pain, stiffness, and impaired physical function in OA. Lumiracoxib shows clinically comparable efficacy and superior tolerability to diclofenac.",
keywords = "Diclofenac, Lumiracoxib, Osteoarthritis, Pain relief",
author = "Schnitzer, {Thomas J.} and Jannie Beier and Piet Geusens and Paul Hasler and Patel, {Sanjay K.} and Ingo Senftleber and Xavier Gitton and Alan Moore and Sloan, {Victor S.} and G. Po{\'o}r",
year = "2004",
month = "8",
day = "15",
language = "English",
volume = "51",
pages = "549--557",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis

T2 - A phase II, four-week, multicenter, randomized, double-blind, placebo controlled trial

AU - Schnitzer, Thomas J.

AU - Beier, Jannie

AU - Geusens, Piet

AU - Hasler, Paul

AU - Patel, Sanjay K.

AU - Senftleber, Ingo

AU - Gitton, Xavier

AU - Moore, Alan

AU - Sloan, Victor S.

AU - Poór, G.

PY - 2004/8/15

Y1 - 2004/8/15

N2 - Objective. To compare the efficacy and tolerability of the novel cyclooxygenase 2-selective inhibitor lumiracoxib with placebo and diclofenac in osteoarthritis (OA). Methods. Adults (n = 583) with knee or hip OA were randomized to receive for 4 weeks lumiracoxib 50, 100, or 200 mg twice daily or 400 mg once daily; placebo; or diclofenac 75 mg twice daily. Efficacy assessments included overall joint pain intensity and Western Ontario and McMaster Universities Osteoarthritis Index subscales; tolerability was evaluated by adverse event and physician reporting. Results. All lumiracoxib doses were superior to placebo in relieving pain, improving stiffness, and improving physical function after 4 weeks. At study endpoint, pain relief was comparable among all lumiracoxib dosages and similar to diclofenac. Lumiracoxib tolerability was superior to diclofenac and comparable to placebo. Conclusion. Lumiracoxib provides predictable and sustained relief from pain, stiffness, and impaired physical function in OA. Lumiracoxib shows clinically comparable efficacy and superior tolerability to diclofenac.

AB - Objective. To compare the efficacy and tolerability of the novel cyclooxygenase 2-selective inhibitor lumiracoxib with placebo and diclofenac in osteoarthritis (OA). Methods. Adults (n = 583) with knee or hip OA were randomized to receive for 4 weeks lumiracoxib 50, 100, or 200 mg twice daily or 400 mg once daily; placebo; or diclofenac 75 mg twice daily. Efficacy assessments included overall joint pain intensity and Western Ontario and McMaster Universities Osteoarthritis Index subscales; tolerability was evaluated by adverse event and physician reporting. Results. All lumiracoxib doses were superior to placebo in relieving pain, improving stiffness, and improving physical function after 4 weeks. At study endpoint, pain relief was comparable among all lumiracoxib dosages and similar to diclofenac. Lumiracoxib tolerability was superior to diclofenac and comparable to placebo. Conclusion. Lumiracoxib provides predictable and sustained relief from pain, stiffness, and impaired physical function in OA. Lumiracoxib shows clinically comparable efficacy and superior tolerability to diclofenac.

KW - Diclofenac

KW - Lumiracoxib

KW - Osteoarthritis

KW - Pain relief

UR - http://www.scopus.com/inward/record.url?scp=19244365254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19244365254&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 549

EP - 557

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 4

ER -